Skip to content

Author

K. Durinck

We have 3 of 91 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Pharmacologically targeting CDK12 induces BRCAness and synergizes with merestinib to exacerbate DNA damage in high-risk neuroblastoma.

High-risk neuroblastoma remains a leading cause of pediatric cancer mortality, underscoring the need for novel therapeutics. MYCN amplification drives transcriptional addiction, creating vulnerabilities for therapeutic intervention. Inhibition of CDK12, a key regulator of transcription elongation, downregulates DNA dam...

J. Goulding, Stijn T. Couwenbergh, Sarah-Lee Bekaert et al. · 0 citations
Review Open access Aug 2026

A functional landscape for chromosome 17q in neuroblastoma: balancing replication stress and genomic stability.

Improved understanding of the mechanisms by which 17q copy number-driven genes regulate replication stress responses and DNA damage repair may expose fundamental vulnerabilities in aggressive neuroblastoma and guide the development of novel targeted therapeutic strategies.

E. Hilgert, L. Depestel, N. Van Roy et al. · 0 citations
Jul 2026

SOX11 stimulates γδ T-cell differentiation and synergizes with LMO2 and MYCN to drive γδ-like T-cell acute lymphoblastic leukemia

Functional validation using genetic and transplantation-based mouse models demonstrated that SOX11 cooperates with MYCN to accelerate T-ALL onset and establish a cooperative SOX11–MYCN oncogenic axis driving γδ-like T-ALL.

André Almeida, Igor Fijalkowski, K. Christensen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.